PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 1999 October; 81(3): 559–563.
PMCID: PMC2362907

Hormone replacement therapy and risk of epithelial ovarian cancer

Abstract

It has been suggested that oestrogen replacement therapy is associated with risk of epithelial ovarian cancer of the endometrioid type. Using data from an Australian population-based case–control study, the relation between unopposed oestrogen replacement therapy and epithelial ovarian cancer, both overall and according to histological type, was examined. A total of 793 eligible incident cases of epithelial ovarian cancer diagnosed from 1990 to 1993 among women living in Queensland, New South Wales and Victoria were identified. These were compared with 855 eligible female controls selected at random from the electoral roll, stratified by age and geographic region. Trained interviewers administered standard questionnaires to obtain detailed reproductive and contraceptive histories, as well as details about hormone replacement therapy and pelvic operations. No clear associations were observed between use of hormone replacement therapy overall and risk of ovarian cancer. Unopposed oestrogen replacement therapy was, however, associated with a significant increase in risk of endometrioid or clear cell epithelial ovarian tumours (odds ratio (OR) 2.56; 95% confidence interval (CI) 1.32–4.94). In addition, the risk associated with oestrogen replacement therapy was much larger in women with an intact genital tract (OR 3.00; 95% Cl 1.54–5.85) than in those with a history of either hysterectomy or tubal ligation. Post-menopausal oestrogen replacement therapy may, therefore, be a risk factor associated with endometrioid and clear cell tumours in particular. Additionally, the risk may be increased predominantly in women with an intact genital tract. These associations could reflect a possible role of endometriosis in the development of endometrioid or clear cell ovarian tumours. © 1999 Cancer Research Campaign

Keywords: ovarian neoplasms, case–control study, oestrogen replacement therapy

Full Text

The Full Text of this article is available as a PDF (67K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 Feb;15(1):10–17. [PubMed]
  • Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer. 1989 Oct;60(4):592–598. [PMC free article] [PubMed]
  • Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst. 1983 Oct;71(4):711–716. [PubMed]
  • Dennerstein L, Shelley J, Smith AM, Ryan M. Hysterectomy experience among mid-aged Australian women. Med J Aust. 1994 Sep 5;161(5):311–313. [PubMed]
  • Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol. 1998 Sep;92(3):472–479. [PubMed]
  • Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995 Feb;85(2):304–313. [PubMed]
  • Green A, Purdie D, Green L, Dick ML, Bain C, Siskind V. Validity of self-reported hysterectomy and tubal sterilisation. The Survey of Women's Health Study Group. Aust N Z J Public Health. 1997 Jun;21(3):337–340. [PubMed]
  • Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, Ward B. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer. 1997 Jun 11;71(6):948–951. [PubMed]
  • Green PK, Weiss NS, McKnight B, Voigt LF, Beresford SA. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control. 1996 Nov;7(6):575–580. [PubMed]
  • Greven KM, Corn BW. Endometrial cancer. Curr Probl Cancer. 1997 Mar-Apr;21(2):65–127. [PubMed]
  • Hartge P, Hoover R, McGowan L, Lesher L, Norris HJ. Menopause and ovarian cancer. Am J Epidemiol. 1988 May;127(5):990–998. [PubMed]
  • Hempling RE, Wong C, Piver MS, Natarajan N, Mettlin CJ. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol. 1997 Jun;89(6):1012–1016. [PubMed]
  • Kaufman DW, Kelly JP, Welch WR, Rosenberg L, Stolley PD, Warshauer ME, Lewis J, Woodruff J, Shapiro S. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol. 1989 Dec;130(6):1142–1151. [PubMed]
  • La Vecchia C, Liberati A, Franceschi S. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 1982 Dec;69(6):1207–1207. [PubMed]
  • Metzger DA, Haney AF. Etiology of endometriosis. Obstet Gynecol Clin North Am. 1989 Mar;16(1):1–14. [PubMed]
  • Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer. 1989 Mar;59(3):445–447. [PMC free article] [PubMed]
  • Paulson RJ. Fertility drugs and ovarian epithelial cancer: the endometriosis hypothesis. J Assist Reprod Genet. 1997 Apr;14(4):228–230. [PubMed]
  • Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N, Quinn M, Wright G, Russell P, Susil B. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. Int J Cancer. 1995 Sep 15;62(6):678–684. [PubMed]
  • Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol. 1996 Nov;63(2):254–257. [PubMed]
  • Rodriguez C, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ, Heath CW., Jr Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol. 1995 May 1;141(9):828–835. [PubMed]
  • Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF, Jr, Nikrui N, Goff BA. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol. 1996 Feb;60(2):238–244. [PubMed]
  • Scully RE. Ovarian tumors. A review. Am J Pathol. 1977 Jun;87(3):686–720. [PubMed]
  • Smith M, McCartney AJ. Occult, high-risk endometrial cancer. Gynecol Oncol. 1985 Oct;22(2):154–161. [PubMed]
  • Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE, Liff JM, Daling JR. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 1982 Jan;68(1):95–98. [PubMed]
  • Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992 Nov 15;136(10):1184–1203. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK